EphA2 as a new target for breast cancer and its potential clinical application

The aim of this research was to study the expression of EphA2 to assess its suitability as a new breast cancer target. Immunohistochemistry (IHC) was used to detect EphA2 protein expression in pathology tissue samples from 250 cases of breast cancer, and the expression of EphA2 mRNA was detected by...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical and experimental pathology 2021-01, Vol.14 (4), p.484-492
Main Authors: Zhou, Lingzhi, Lu, Xuejing, Zhang, Bensi, Shi, Yaqi, Li, Zhuang
Format: Article
Language:English
Subjects:
Original
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this research was to study the expression of EphA2 to assess its suitability as a new breast cancer target. Immunohistochemistry (IHC) was used to detect EphA2 protein expression in pathology tissue samples from 250 cases of breast cancer, and the expression of EphA2 mRNA was detected by in situ hybridization (ISH). Breast cancer cells were isolated and cultured. The expression of EphA2 in the cells was detected by the indirect immunofluorescence assay (IFA), and the expression of EphA2 in breast cancer was analysed. EphA2 protein and mRNA were mainly expressed in tumor cells and vascular endothelial cells. EphA2 protein was expressed in 187 cases, with a positive rate of 74.80%, whereas EphA2 mRNA was expressed in 209 cases, with a positive rate of 83.60%. EphA2 protein and mRNA expression were correlated with lymph node metastasis, clinical stage, and breast cancer histologic grade (P
ISSN:1936-2625